CG Oncology
CGON • NASDAQ
CG Oncology is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Arthur Kuan, with a market cap of $5.5B.
CEOArthur Kuan
Next Earnings
Upcoming earnings announcement for CG Oncology
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.55
Revenue Estimate
$511.8K
Earnings History
Past 8 earnings reports for CG Oncology
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | Q4 2025 | -$0.51Est: -$0.59 | +13.6% | $2.3MEst: $1.6M | +41.5% |  10-K |
| Nov 14, 2025 | Q3 2025 | -$0.57Est: -$0.56 | -1.8% | $1.7MEst: $175.5K | +849.1% | 10-Q |
| Aug 8, 2025 | Q2 2025 | -$0.54Est: -$0.46 | -17.4% | -Est: $197.2K | -100.0% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.45Est: -$0.28 | -60.7% | $52.0KEst: $144.6K | -64.0% | 10-Q |
| Mar 28, 2025 | Q4 2024 | -$0.46Est: -$0.39 | -17.9% | $456.0KEst: $51.5K | +784.9% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.30Est: -$0.36 | +16.7% | -Est: $100.0K | -100.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.28Est: -$0.37 | +24.3% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.36Est: -$0.31 | -16.1% | - | — | 10-Q |